SOURCE: SciClone Pharmaceuticals, Inc.

September 19, 2005 06:30 ET

SciClone Pharmaceuticals to Present at UBS Global Life Sciences Conference

SAN MATEO, CA -- (MARKET WIRE) -- September 19, 2005 -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will present at the UBS Global Life Sciences conference at the Grand Hyatt New York. Ira D. Lawrence, M.D., SciClone's President and Chief Executive Officer, will deliver a corporate overview presentation on Tuesday, September 27, 2005 at 3:00 p.m. EDT.

To access the live audio webcast of the presentation, log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com. A replay of the webcast will be available until October 29, 2005.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in two phase 3 hepatitis C clinical trials in the United States and one hepatitis C triple therapy clinical trial in Europe. ZADAXIN also is being evaluated in other late-stage clinical trials for the treatment of hepatitis B and certain cancers. The company's other principal drug development candidate is SCV-07, currently in phase 1 development, which is being evaluated for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

The information in Dr. Lawrence’s presentation may contain forward-looking statements, including our expectations and beliefs regarding future sales of our products, plans and expectations for 2005, and expectations regarding both of our phase 3 hepatitis C clinical trials. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, goals, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including changes in demand for ZADAXIN, the progress or failure of clinical trials, our actual experience in executing on our objectives, the performance of our partners, maintenance of the sufficiency and eligibility of the enrolled patient population, unanticipated delays or additional expenses incurred during our clinical trials, our future cash requirements, delays in analyzing and synthesizing data obtained from clinical trials, future actions of our strategic partners, unexpected delays in preparation for enrollment, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in Europe and the fact that experimental data and clinical results derived from studies with a limited group of patients may not be predictive of the results of larger studies, as well as other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission.

Contact Information

  • Corporate information contact:

    Becky Horner
    Investor Relations
    SciClone Pharmaceuticals, Inc.
    650-358-3437